Bevacizumab in ovarian cancer [4]

New England Journal of Medicine

Volumn 366, Issue 13, 2012, Pages 1256-1258

  Korn, Edward L ^a   Freidlin, Boris ^a   Abrams, Jeffrey S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER PATIENT; CANCER SURVIVAL; DISEASE COURSE; HUMAN; LETTER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; DRUG EFFICACY; DRUG TOLERABILITY; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME; FEMALE; NEOPLASM; NOTE; OVARY TUMOR;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84859024373     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1201044     Document Type: Letter

References (5)

1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
2. Stuart GCE, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21:750-5.
3. Cannistra SA. Evaluating new regimens inrecurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 2010;28:3101-3.
4. Korn EL, Freidlin B, Abrams JS. Overall survival asthe outcome of randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-42.
5. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96. [Erratum, N Engl J Med 2012;366:284.]